Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

Novo Nordisk said that if approved for use, insulin icodec would reduce the number of basal insulin injections needed per year for type 2 diabetics from 365 to 52, a significant reduction in ...

On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and ...

Two widely prescribed drugs for type 2 diabetes—sulfonylureas and basal insulin—may increase the risk of severe ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

Here are 10 things - including the weather - that can positively or negatively impact how your metabolism works.

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases.

A debt-ridden global diabetes care company that won FDA approval for its first wearable insulin delivery system in the summer will lay off more than 100 workers at its Massachusetts facility.